Giada Bianchi

Hematology | Oncology
75 Francis St
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 94 publications

Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 03, 2026

Elranatamab: A novel B-cell maturation T-cell engager.

Elranatamab: A novel B-cell maturation T-cell engager.

Journal: Human vaccines & immunotherapeutics
Published: July 08, 2026

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 29, 2026

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Journal: Haematologica
Published: March 13, 2026

Assessment of cardiac involvement in rare forms of amyloidosis using positron emission tomography/computed tomography with 124I-evuzamitide (124I-p5+14, AT-01).

Assessment of cardiac involvement in rare forms of amyloidosis using positron emission tomography/computed tomography with 124I-evuzamitide (124I-p5+14, AT-01).

Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Published: February 05, 2026

Assessment of Cardiac Involvement in Rare Forms of Amyloidosis Using PET/CT with 124I-Evuzamitide (124I-p5+14, AT-01).

Assessment of Cardiac Involvement in Rare Forms of Amyloidosis Using PET/CT with 124I-Evuzamitide (124I-p5+14, AT-01).

Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Published: February 05, 2026

Thin Glomerular Basement Membrane Phenotypes With No Identified Pathogenic COL4A3/A4/A5 Variant.

Thin Glomerular Basement Membrane Phenotypes With No Identified Pathogenic COL4A3/A4/A5 Variant.

Journal: Kidney international reports
Published: January 11, 2026

Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey.

Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey.

Journal: Clinical lymphoma, myeloma & leukemia
Published: November 10, 2025

Mezigdomide for multiple myeloma: a focus on phase 2 trial data.

Mezigdomide for multiple myeloma: a focus on phase 2 trial data.

Journal: Expert opinion on emerging drugs
Published: October 30, 2025

Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy.

Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy.

Journal: JACC. CardioOncology
Published: October 14, 2025

The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis.

The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis.

Journal: American journal of hematology
Published: September 27, 2025

The Association of Kidney Function on Survival in Patients with Amyloid Light Chain Amyloidosis after Autologous Stem Cell Transplantation: A Multicenter Study.

The Association of Kidney Function on Survival in Patients with Amyloid Light Chain Amyloidosis after Autologous Stem Cell Transplantation: A Multicenter Study.

Journal: Kidney360
Published: July 08, 2025
Showing 1-12 of 94

Last Updated: 09/26/2026